1071517-39-9

Basic information

• Product Name: N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide
• Synonyms: N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide;Setrobuvir (ANA598);Setrobuvir;N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiad
• CAS NO: 1071517-39-9
• Molecular Formula: C₂₅H₂₅FN₄O₆S₂
• Molecular Weight: 560.6176032
• Mol File: 1071517-39-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.72
• CAS DataBase Reference: N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide(1071517-39-9)
• EPA Substance Registry System: N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide(1071517-39-9)

Safety Data

• Hazardous Substances Data: 1071517-39-9(Hazardous Substances Data)

Usage

General Description

The chemical N-[3-[(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-1,2,4a,5,6,7,8,8a-octahydro-4-hydroxy-2-oxo-5,8-methanoquinolin-3-yl]-1,1-dioxido-2H-1,2,4-benzothiadiazin-7-yl]methanesulfonamide is a complex compound with a long and complex name. It is a sulfonamide derivative with a benzothiadiazine structure, containing a quinolinone and a fluorophenylmethyl group. This chemical compound has potential pharmacological activities and may be used in the development of new drugs. Due to its complex structure, it may require specialized synthetic methods for its preparation and purification.

Upstream product

• 96-73-1 2-chloro-5-nitro-benzenesulfonic acid 
• 1071519-76-0 2,5-diamino-benzenesulfonamide methanesulfonate 
• 105786-35-4 (rac-di-exo)-3-amino-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 95630-75-4 ethyl exo-3-aminobicyclo<2.2.1>heptane-2-exo-carboxylate hydrochloride 
• 179462-36-3 (±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride 
• 7486-95-5 exo-3-azatricyclo<4.2.1.0^2,5>nonan-4-one 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 1071520-32-5 (1S,2S,3R,4R)-3-ethoxycarbonyl-bicyclo[2.2.1]hept-2-yl-ammonium (1'S)-(+)-10-camphorsulfonate 
• 1071520-19-8 methyl (1S,2R,3S,4R)-3-amino-bicyclo[2.2.1]heptane-2-carboxylate hydrochloride 
• 1071520-16-5 (1R,2R,3S,4S)-3-benzyloxycarbonylamino-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid methyl ester 
• 1071520-41-6 (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1000313-20-1 (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[e][1,2,4]thiadiazin-3-yl)-acetic acid 
• 1000313-19-8 N-(4-methanesulfonylamino-2-sulfamoylphenyl)malonamic acid methyl ester 
• 1000313-18-7 N-(4-(methanesulfonylamino)-2-sulfamoyl-phenyl)malonamic acid ethyl ester 

Downstream Products

• 1071519-59-9 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-arginine salt 
• 1071519-66-8 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide sodium salt 
• 1071519-68-0 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide potassium salt 
• 1071519-62-4 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-lysine salt 

Relevant articles and documents

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID

The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.